ArticleEFSA journal. European Food Safety Authority2026
Flavouring Group Evaluation 82 Revision 2 (FGE.82Rev2): Consideration of epoxides evaluated by JECFA.
Article in EFSA journal. European Food Safety Authority, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Flavouring Group Evaluation 82 Revision 2 (FGE.82Rev2): Consideration of epoxides evaluated by JECFA.EFSA journal. European Food Safety Authority · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Panel on Food Additives and Flavourings (FAF) of the European Food Safety Authority was requested to consider evaluations of flavouring substances assessed since 2000 by the Joint FAO/WHO Expert Committee on Food Additives (JECFA), and to decide whether further evaluation is necessary, as laid down in Commission Regulation (EC) No. 1565/2000. The present consideration concerns a group of five epoxides evaluated by JECFA at the 65th meeting. This revision of FGE.82 is made due to new information on stereoisomeric composition, toxicity studies, uses and use levels for beta-ionone epoxide [FL-no: 07.170]. In addition, new data on uses and use levels for the substances [FL-no: 16.015, 16.018, 16.040 and 16.043] have been provided and considered for the estimation of exposure (modified theoretical added maximum daily intake (mTAMDI) approach). The Panel considered that the information on the stereochemical composition of [FL-no: 07.170] is sufficient. The Panel did not agree with the application of the Procedure for the epoxides as performed by JECFA, because in the absence of experimental data, the extent of detoxification of these epoxides remains uncertain. Therefore, [FL-no: 07.170] was assessed via the B-side of the Procedure. In the 90-day toxicity study on [FL-no: 07.170], substance-related findings were observed in adrenal glands of male rats. Based on this observation, the Panel identified a no observed adverse effect level (NOAEL) of 39 mg/kg bw per day and concluded that for [FL-no: 07.170] there is 'no safety concern at estimated levels of intake as flavouring substance', when based on the maximised survey-derived daily intake (MSDI) approach. Based on new information on uses and use levels for [FL-no: 07.170, 16.015, 16.018, 16.040 and 16.043], the mTAMDI exposure estimates are above the toxicological threshold of concern (TTC) for their structural class III. The Panel concluded that more reliable data on uses and use levels would be needed for these five substances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.